ASX:RAC

Race Oncology Limited - RAC share price

$ - -

About Race Oncology Limited

Race Oncology Limited is an Australian precision oncology company. They're developing a cancer drug called Zantrene, which targets the FTO protein. Zantrene is being explored as a potential therapy for melanoma and clear cell renal cell carcinoma, both linked to FTO. It acts as a precise, low-dose oncology agent and a cardio-protective chemotherapeutic. The drug also shows promise in reducing cardiotoxicity in acute myeloid leukemia, breast, and ovarian cancers. Race Oncology is dedicated to advancing Zantrene as a cancer treatment with a focus on improving chemotherapy outcomes.

Company Profile

Market Cap -

Book Value -

Enterprise Value -

Revenue TTM -

Shares Outstanding -

Earning Share

Shares Float -

Dividend per Share

P/E Ratio -

Div Yield -

Disclaimer: The above financial data is sourced from EODHD and is for informational purposes only. Veye does not guarantee the accuracy or completeness of this data. Investors should conduct their own research and consult with a financial advisor before making investment decisions.

Price Summary

Today's Low Today's High

- -

52 Week High

52 Week Low

Price Chart (RAC)

TOP ASX STOCKS Worth Watching

✓ Instant Access
✓ No Credit Card Required
✓ Free to join · No spam

Get Free Report on WhatsApp

Free to join · No spam · Unsubscribe anytime

Special Research Report

Discover the Top ASX Stocks to Invest in 2026!

Expert Analysis of Top-Performing ASX Stocks

Market Insights and In-Depth Research

Buy, Sell, And Hold Recommendations

Almost There!

Enter your details to download the report

Full Name

Email Address

Phone Number

By providing your details, you agree to Veye’s Terms & Conditions, Privacy Policy, and Financial Services Guide and to receive marketing offers by email, text message or phone call from us or our agents until you opt out. Before you access our services, please read the Financial Service Guide available here.